JP2023520333A5 - - Google Patents
Info
- Publication number
- JP2023520333A5 JP2023520333A5 JP2022557856A JP2022557856A JP2023520333A5 JP 2023520333 A5 JP2023520333 A5 JP 2023520333A5 JP 2022557856 A JP2022557856 A JP 2022557856A JP 2022557856 A JP2022557856 A JP 2022557856A JP 2023520333 A5 JP2023520333 A5 JP 2023520333A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- alkyl
- inhibitor
- pharmaceutical product
- product according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062993889P | 2020-03-24 | 2020-03-24 | |
| US62/993,889 | 2020-03-24 | ||
| PCT/US2021/023752 WO2021195128A1 (en) | 2020-03-24 | 2021-03-23 | Eif4a inhibitor combinations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023520333A JP2023520333A (ja) | 2023-05-17 |
| JP2023520333A5 true JP2023520333A5 (https=) | 2024-04-03 |
Family
ID=77855108
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022557856A Pending JP2023520333A (ja) | 2020-03-24 | 2021-03-23 | Ｅｉｆ４ａ阻害剤組み合わせ |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20210299111A1 (https=) |
| EP (1) | EP4125884A4 (https=) |
| JP (1) | JP2023520333A (https=) |
| KR (1) | KR20230005175A (https=) |
| CN (1) | CN115996716A (https=) |
| AU (1) | AU2021244462A1 (https=) |
| CA (1) | CA3176264A1 (https=) |
| WO (1) | WO2021195128A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4395775A1 (en) | 2021-09-01 | 2024-07-10 | KHR Biotec GmbH | Cyclopenta[4,5]furo[3,2-c]pyridine derivatives as ras inhibitors for use in the treatment of hyperproliferative diseases or genetic disorders |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| WO2024254195A1 (en) * | 2023-06-06 | 2024-12-12 | Baylor University | Methods for treating pancreatic cancer with a combination of des-methyl pateamine a and a class 1 hdac inhibitor |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| CN119351519B (zh) * | 2024-10-21 | 2025-08-01 | 吉林大学 | 一种靶向隐孢子虫解旋酶的抗隐孢子虫小分子先导化合物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102011111400A1 (de) * | 2011-08-23 | 2013-02-28 | Merck Patent Gmbh | Bicyclische heteroaromatische Verbindungen |
| EP3191098A4 (en) * | 2014-09-12 | 2018-04-25 | G1 Therapeutics, Inc. | Combinations and dosing regimes to treat rb-positive tumors |
| DK3888658T3 (da) * | 2015-11-25 | 2024-03-18 | Effector Therapeutics Inc | Eif4-a-inhiberende forbindelser og fremgangsmåder relateret dertil |
| CA3063563A1 (en) * | 2017-05-24 | 2018-11-29 | Effector Therapeutics, Inc. | Compositions and methods for an improved antitumor immune response |
-
2021
- 2021-03-23 CA CA3176264A patent/CA3176264A1/en active Pending
- 2021-03-23 JP JP2022557856A patent/JP2023520333A/ja active Pending
- 2021-03-23 WO PCT/US2021/023752 patent/WO2021195128A1/en not_active Ceased
- 2021-03-23 AU AU2021244462A patent/AU2021244462A1/en not_active Abandoned
- 2021-03-23 EP EP21776812.6A patent/EP4125884A4/en not_active Withdrawn
- 2021-03-23 KR KR1020227036983A patent/KR20230005175A/ko active Pending
- 2021-03-23 US US17/210,062 patent/US20210299111A1/en not_active Abandoned
- 2021-03-23 CN CN202180037497.2A patent/CN115996716A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023520333A5 (https=) | ||
| ES2911040T3 (es) | Nuevos derivados de heteroaril amida como inhibidores selectivos de histona deacetilasa 1 y 2 (HDAC1/2) | |
| US20090041716A1 (en) | Crystalline form of methyl ((1s)-1-(((2s)-2-(5-(4'-(2-((2s)-1((2s)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1h-imidazol-5-yl)-4-biphenylyl)-1h-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt | |
| BR112020001695A2 (pt) | compostos macrocíclicos e usos dos mesmos | |
| JP2019517487A5 (https=) | ||
| JP2011509309A5 (https=) | ||
| WO2012143248A1 (en) | Substituted pyrimidinyl-pyrroles active as kinase inhibitors | |
| JP2023536164A5 (https=) | ||
| US8987288B2 (en) | Heterocyclic aminoberbamine derivatives, the preparation process and use thereof | |
| JP2016525104A5 (https=) | ||
| US9714235B2 (en) | Quinazoline derivatives, compositions thereof, and use as pharmaceuticals | |
| CN111511745A (zh) | 吡唑并[1,5-a][1,3,5]三嗪-2-胺类衍生物、其制备方法及其在医药上的应用 | |
| WO2022083657A1 (zh) | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 | |
| US10947225B2 (en) | Phosphotidylinositol 3-kinase inhibitors | |
| US20160229857A1 (en) | Substituted pyrrolo[2,3-d]dipyrimidines for selectively targeting tumor cells with fr-alpha and fr-beta type receptors | |
| JP2017137323A (ja) | 新規抗がん剤 | |
| WO2018117196A1 (ja) | がん幹細胞を標的とする医薬 | |
| CN101265275B (zh) | 4-{6-[5-(2-氯-6-甲基苯胺甲酰基)-噻唑-2-氨基]-2-甲基嘧啶-4}-哌嗪-1-磷酸二乙酯 | |
| CA3119036A1 (en) | Anti-cancer activity of adamantane derivatives | |
| JP2022502378A5 (https=) | ||
| CA3195465A1 (en) | Succinate and crystal form thereof as therapeutics | |
| CN110520118A (zh) | 谷氨酰胺类似物的前药 | |
| US10093609B2 (en) | TAK1 kinase inhibitors, compositions, and uses related thereto | |
| JP2022521474A5 (https=) | ||
| CN108498518B (zh) | 七元环小檗碱类似物及其药物组合物在制备治疗多发性骨髓瘤的药物中的应用 |